Pacira BioSciences Balance Sheet Health
Financial Health criteria checks 5/6
Pacira BioSciences has a total shareholder equity of $892.2M and total debt of $520.3M, which brings its debt-to-equity ratio to 58.3%. Its total assets and total liabilities are $1.6B and $691.2M respectively. Pacira BioSciences's EBIT is $93.4M making its interest coverage ratio 51.1. It has cash and short-term investments of $325.9M.
Key information
58.3%
Debt to equity ratio
US$520.33m
Debt
| Interest coverage ratio | 51.1x |
| Cash | US$325.89m |
| Equity | US$892.16m |
| Total liabilities | US$691.16m |
| Total assets | US$1.58b |
Recent financial health updates
Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well
Apr 04Recent updates
Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well
Apr 04Pacira BioSciences: Higher Prices On The Horizon
Dec 20Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects
Nov 29Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly
Oct 15Financial Position Analysis
Short Term Liabilities: PCRX's short term assets ($543.1M) exceed its short term liabilities ($93.4M).
Long Term Liabilities: PCRX's short term assets ($543.1M) do not cover its long term liabilities ($597.7M).
Debt to Equity History and Analysis
Debt Level: PCRX's net debt to equity ratio (21.8%) is considered satisfactory.
Reducing Debt: PCRX's debt to equity ratio has reduced from 89.9% to 58.3% over the past 5 years.
Debt Coverage: PCRX's debt is well covered by operating cash flow (35.5%).
Interest Coverage: PCRX's interest payments on its debt are well covered by EBIT (51.1x coverage).